A new generic drugmaker said it was awarded $354 million in federal funding to make prescription drugs and their raw ingredients in the U.S., including some medicines used to treat patients infected with Covid-19.

Privately held Phlow Corp., a Richmond, Va.-based company incorporated earlier this year, said the funding will support manufacture that began recently of more than a dozen generic prescription drugs in short supply that are used to treat Covid-19 patients.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here